Cyclacel Pharmaceuticals Inc (CYCC) Stock
CYCC is no longer traded. Cyclacel Pharmaceuticals was delisted from the Nasdaq in September 2025.
Prices on this page are historical; the last trade was September 11, 2025 at $6.37.
Cyclacel Pharmaceuticals stock price history
CYCC final trading statistics
- Final close
- $6.37
- Final trading day
- Sep 11, 2025
- Market cap at delisting
- $14.25M
- Shares outstanding
- 2.24M
- Final 52-week range
- $0.17 – $19.87
- Avg. volume (final 3 mo.)
- 1,863,977
- All-time high (split-adj.)
- $1000000.00 · Mar 2004
- All-time low (split-adj.)
- $3.31 · Jul 2025
- Return since IPO
- -100.0%
- Beta
- 0.16
- Book value / share
- $2.29
- Price / book
- 2.78
Cyclacel Pharmaceuticals annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2024 | $43.0K | -$11.2M | — |
| FY2023 | $420.0K | -$22.6M | -$7.63 |
| FY2022 | $373.0K | -$21.2M | -$1.90 |
| FY2021 | $0.00 | -$18.9M | -$2.14 |
| FY2020 | $5.9K | -$8.4M | -$3.87 |
Last five fiscal years reported before the delisting; fiscal year ending December. EPS is adjusted (non-GAAP) EPS as reported. Source: company filings via EODHD.
About Cyclacel Pharmaceuticals Inc
Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops cancer medicines based on cell cycle, transcriptional regulation, epigenetics, and mitosis control biology in the United States. Its lead product Plogosertib or plogo, a solid tumors and hematological malignancies, which is in Phase 1/2 clinical trial. The company was founded in 1996 and is headquartered in Kuala Lumpur, Malaysia.
Cyclacel Pharmaceuticals stock FAQ
What happened to Cyclacel Pharmaceuticals stock?
Cyclacel Pharmaceuticals stock was delisted from the Nasdaq. Its final close was $6.37 on September 11, 2025.
Is CYCC stock still trading?
No. CYCC was delisted from the Nasdaq in September 2025 and no longer trades on a U.S. exchange.
What was the last price of CYCC stock?
CYCC closed at $6.37 on its final trading day, September 11, 2025, for a market value of about $14.25M.
What were Cyclacel Pharmaceuticals's revenue and earnings in its last full fiscal year?
Cyclacel Pharmaceuticals reported revenue of $43.0K and net income of -$11.2M in fiscal 2024, its last full year as a public company.
When did Cyclacel Pharmaceuticals go public?
Cyclacel Pharmaceuticals Inc stock began trading on May 5, 2004.